Incyte is a U.S.-based biopharmaceutical company that discovers, develops, and commercializes proprietary medicines. Its business is concentrated in hematology, oncology, and inflammation/autoimmunity, with revenue driven by marketed drugs such as JAKAFI, OPZELURA, MONJUVI/MINJUVI, and NIKTIMVO plus royalties and collaboration income.
31,3 %
92,8 %
25,0 %
+21,2 %
3.32
3.25
| % | |
|---|---|
| Commercial hematology products | 55% Approved medicines for myelofibrosis, polycythemia vera, GVHD, and related blood cancers. |
| Dermatology / inflammation products | 25% Topical and systemic therapies for inflammatory skin and immune-mediated diseases. |
| Royalty revenue | 10% Royalties earned from partnered products sold by collaborators in certain markets. |
| Collaborations and licensing | 10% Upfront, milestone, and other collaboration-related revenue from partnered R&D programs. |
Incyte sells primarily to specialty and retail pharmacies, specialty distributors, wholesalers, hospital pharmacies,...
Buy and dispense Incyte's branded medicines, especially chronic therapies like JAKAFI and OPZELURA.
Purchase therapies used in GVHD and oncology settings where administration and reimbursement are hospital-linked.
Prescribe Incyte's medicines to patients with hematologic malignancies, GVHD, and inflammatory skin disease.
Commercialize partnered assets in certain geographies and pay royalties or milestones to Incyte.
Incyte is globally organized, with headquarters and commercial operations in Wilmington, Delaware, plus major regional...
Incyte's strategy is to develop and commercialize internally discovered or in-licensed therapies in markets where it...
More indications and more geographies increase the lifetime value of each asset.
Pipeline success is needed to offset eventual patent expiry and sustain growth.
Partners can provide local expertise, funding, and commercialization scale.
Incyte faces typical biopharma risks around clinical trial failure, regulatory approval, patent protection, and product...
A large share of revenue comes from a small number of therapies, so any demand slowdown or competition can materially affect results.
Pipeline assets require successful trials and approvals, and failures can remove expected future revenue streams.
Antibody manufacturing is complex and depends on contract manufacturers and regulatory approvals for facilities.
Loss of patent protection or successful challenges can reduce pricing power and royalty value.
Adverse events or perceived safety issues can reduce prescribing and trigger claims or label restrictions.
INCY · Services-Commercial Physical & Biological Research
Incyte is a U.S.-based biopharmaceutical company that discovers, develops, and commercializes proprietary medicines.
PMCB · Biological Products, (No Diagnostic Substances)
MXCT · Services-Commercial Physical & Biological Research
MaxCyte is a cell-engineering tools and platform company built around its Flow Electroporation technology and ExPERT instrument family.
UNCY · Pharmaceutical Preparations
VCYT · Services-Medical Laboratories
Veracyte is a U.S.-based molecular diagnostics company that develops and commercializes genomic tests used in cancer and other disease areas.
PCVX · Biological Products, (No Diagnostic Substances)
: 11/08/2026